Follows androgen hormones and fatty liver disease in young women with or without PCOS
Follows androgen hormones and fatty liver in young women, with and without PCOS.
Key facts
- Who runs it
- University of California, San Francisco
- Where
- Durham and San Francisco, United StatesSee the 2 sites
- Trial code
- Registry title
- Androgens and NAFLD Longitudinal Cohort Study
- Status
- Recruiting
- People taking part
- 150 people, planned
- Started
- 22 Jan 2024
- Expected to end
- Dec 2028
- Type of study
- Observational, 3 groups
- Record updated
- 13 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for young women with and without polycystic ovary syndrome (PCOS) to study how androgens affect fatty liver over time.
- Age
- 18 to 42 years
- Sex
- Women only
- Disease stage
- Metabolic associated steatohepatitis (MASH, formerly NASH), with or without PCOS.
Main reasons for not taking part
- High alcohol use (more than 7 drinks a week)
- Current pregnancy
- Other causes of fatty liver (hepatic steatosis)
- Weight loss of more than 10% body weight in the last 6 months
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Metabolic associated steatohepatitis (MASH) (formerly NASH)
- PCOS
- Non-PCOS
Who cannot take part
- High levels of alcohol use (more than 7 drinks a week)
- Current pregnancy
- Other causes of hepatic steatosis
- Weight loss of more than 10% body weight in the last 6 months
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 42 years old?
Where in United States
- Duke UniversityDurham, United StatesContact: Linda Perry, R.N.Not yet recruiting
- University of California San FranciscoSan Francisco, United StatesContact: Lily C Carbullido, B.S.Taking people
About the trial
What the trial wants to find out
The researchers want to learn how androgens, a type of sex hormone, might affect nonalcoholic fatty liver (NAFLD) in young women over time. NAFLD happens when fat builds up in the liver which can cause damage to the liver such as inflammation or scarring.
Read full original descriptionShow less
Young women with a condition called polycystic ovary syndrome (PCOS) have a high risk for NAFLD, and they often have high androgen levels too. So the researchers are recruiting young women with PCOS as well as those without PCOS, and will compare changes in NAFLD over time between young women with and without PCOS.
This study is funded by the National Institutes of Health
The 3 groups in the trial
- MASLD and PCOS hyperandrogenism
Patients with MASLD and PCOS with the phenotype of hyperandrogenism
- MASLD and PCOS non-hyperandrogenism
Patients with MASLD and PCOS with the phenotype of non-hyperandrogenism
- MASLD and no-PCOS
Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and no PCOS
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Androgens and Nonalcoholic Fatty Liver Disease (NAFLD) In Reproductive-Aged Women With and Without Polycystic Ovary Syndrome (PCOS)
- Plain-language title
- Follows androgen hormones and fatty liver disease in young women with or without PCOSGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06124261, who can take part
- Record updated
- 13 April 2026